| Analysis | Metabolite Name | Measured Value | Units | Genotype | Treatment | Metabolite | Tissue |
|---|---|---|---|---|---|---|---|
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 0.517 | ng/g tissue | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 0.925 | ng/mL | F344 Pirc | AIN-93G (control) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 1.221 | ng/g tissue | F344 Pirc | AIN-93G (control) | Eicosanoid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 1.338 | ng/mL | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 1.519 | ng/g tissue | F344 Pirc | AIN-93G (control) | Eicosanoid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 2.298 | ng/g tissue | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 2.543 | ng/g tissue | F344 Pirc | AIN-93G (control) | Eicosanoid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 3.832 | ng/mL | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 3.842 | ng/mL | F344 Pirc | AIN-93G (control) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 4.440 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 4.809 | ng/mL | F344 Pirc | AIN-93G (control) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 4.816 | ng/mL | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 5.677 | ng/mL | F344 Pirc | AIN-93G (control) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 7.988 | ng/mL | F344 Pirc | AIN-93G (control) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 8.309 | ng/mL | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 9.168 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 10.132 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 10.776 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 11.904 | ng/mL | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 13.860 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 14.550 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 16.641 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 17.878 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 18.091 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 18.745 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 21.993 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 22.161 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 22.239 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 23.878 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 24.639 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 25.001 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 25.076 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 25.090 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 25.746 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 26.777 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 28.736 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 28.868 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 29.208 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 29.330 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 32.986 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 33.100 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 38.030 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 39.330 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 40.611 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 43.807 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 45.370 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 47.734 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 48.255 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 52.158 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 58.616 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 60.955 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 63.604 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 64.695 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 65.737 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 71.192 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 71.319 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | 77.611 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/g tissue | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/g tissue | F344 Pirc | AIN-93G (control) | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/g tissue | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/g tissue | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/g tissue | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/g tissue | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/mL | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | MaR1(n-3DPA) | ng/mL | F344 Pirc | AIN-93G (control) | Eicosanoid | Plasma |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|